Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
California Sues Trump Administration Over Federal Authority on Sable Offshore Pipelines 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Trump Administration Sued Over Suspension of Critical Hudson River Tunnel Funding 
What is commonly known as a party drug is now an actual method of treating patients who are experience post-traumatic stress disorder (PTSD). The US Food and Drug Administration (FDA) has officially classified Ecstasy as a “breakthrough therapy” and is on its way to becoming legally accessible for medicinal purposes.
The news was announced by the Multidisciplinary Association for Psychedelic Studies (MAPS) last week, noting that they can now move forward with their “Phase 3” trials. This is basically where human patients come in and for this particular experiment, over 200 participants are going to be given ecstasy to see just how well the drug helps alleviate the damage caused by PTSD.
Phase 3 will be called "A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder," which builds on the data collected during Phase 2. According to the Executive Director of the MAPS Public Benefit Corporation (MPBC), Amy Emerson, this process will go a lot more smoothly with the approval of the FDA.
"Reaching agreement with FDA on the design of our Phase 3 program and having the ability to work closely with the agency has been a major priority for our team," Emerson said. "Our Phase 2 data was extremely promising with a large effect size, and we are ready to move forward quickly. With breakthrough designation, we can now move even more efficiently through the development process in collaboration with the FDA to complete Phase 3."
The trials will be held in the US, Canada, and Israel, Futurism reports, and MAPS will soon start recruiting participants to join the tests. If all goes well, ecstasy will be joining cannabis as a means of treating illnesses. Speaking of which, marijuana has also been used to treat PTSD patients, which should make some promising and potentially fun possibilities down the road.
